CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice.
Targeted gene delivery to the tissue of interest by recombinant adenovirus (Ad) vectors is limited by the relatively broad expression of the primary receptor, the coxsackievirus and adenovirus receptor (CAR), and the secondary receptor, alphav integrin. This problem could be overcome by mutating the fiber and penton base, which bind with CAR and alphav integrin, respectively. In this study, we constructed CAR-binding ablated Ad vectors and alphav integrin-binding ablated Ad vectors by mutation in the FG loop of fiber knob and in the RGD motif of penton base, respectively, and compared the gene transfer properties of their vectors into various types of cultured cells and mice with conventional Ad vectors. We also generated Ad vectors containing RGD peptide in the HI loop of the fiber knob. CAR-binding ablated Ad vectors mediated about 1% of gene transfer activity into CAR-positive cultured cells, compared with conventional Ad vectors, while alphav integrin-binding ablated Ad vectors maintained at least 76% of gene transfer activity into cultured CAR-positive cells. Inclusion of the RGD peptide into the HI loop of the fiber knob of CAR-binding ablated Ad vectors restored gene transfer activity in vitro. On the other hand, systemically administered CAR-binding ablated Ad vectors, as well as alphav integrin-binding ablated Ad vectors mediated similar levels of gene transfer into mouse liver with the conventional Ad vectors. These results suggest that continued interaction of either the fiber with CAR or the penton base with alphav integrin offers an effective route of virus entry into mouse liver in vivo. Inhibition of the interaction of both the fiber with CAR and the penton base with alphav integrin is likely to be crucial to the development of targeted Ad vectors.
Mizuguchi
H
H
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Tokyo, Japan.
Koizumi
N
N
Hosono
T
T
Ishii-Watabe
A
A
Uchida
E
E
Utoguchi
N
N
Watanabe
Y
Y
Hayakawa
T
T
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002460:Cell Line; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D017353:Gene Deletion; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism; D051379:Mice; D009842:Oligopeptides / Q000235:genetics; D011991:Receptors, Virus / Q000235:genetics*; D019030:Receptors, Vitronectin / Q000235:genetics*; D014161:Transduction, Genetic
C568771:CLMP protein, human; C568772:CLMP protein, mouse; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D009842:Oligopeptides; D011991:Receptors, Virus; D019030:Receptors, Vitronectin; C047981:arginyl-glycyl-aspartic acid